BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 31294484)

  • 1. Patterns of care and outcomes in small cell carcinoma of the prostate: A national cancer database analysis.
    Metzger AL; Abel S; Wegner RE; Fuhrer R; Mao S; Miller R; Beriwal S; Horne ZD
    Prostate; 2019 Sep; 79(12):1457-1461. PubMed ID: 31294484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    Rusthoven CG; Jones BL; Flaig TW; Crawford ED; Koshy M; Sher DJ; Mahmood U; Chen RC; Chapin BF; Kavanagh BD; Pugh TJ
    J Clin Oncol; 2016 Aug; 34(24):2835-42. PubMed ID: 27325855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis.
    Zaffuto E; Pompe R; Zanaty M; Bondarenko HD; Leyh-Bannurah SR; Moschini M; Dell'Oglio P; Gandaglia G; Fossati N; Stabile A; Zorn KC; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2017 Oct; 15(5):e793-e800. PubMed ID: 28506524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit.
    Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW
    BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer.
    Kim AH; Konety B; Chen Z; Schumacher F; Kutikov A; Smaldone M; Abouassaly R; Khanna A; Kim SP
    Urology; 2018 Oct; 120():173-179. PubMed ID: 29990574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base.
    Wong AT; Shao M; Rineer J; Osborn V; Schwartz D; Schreiber D
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27860114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.
    Weiner AB; Patel SG; Richards KA; Szmulewitz RZ; Eggener SE
    Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):286-91. PubMed ID: 25027862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Saad A; Goldstein J; Lawrence YR; Spieler B; Leibowitz-Amit R; Berger R; Davidson T; Urban D; Tsang L; Alezra D; Weiss I; Symon Z
    Radiat Oncol; 2017 Jan; 12(1):5. PubMed ID: 28061904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer.
    Bryant AK; Kader AK; McKay RR; Einck JP; Mell LK; Mundt AJ; Kane CJ; Efstathiou JA; Murphy JD; Rose BS
    Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1188-1193. PubMed ID: 29891203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms.
    Cohen A; Richards KA; Patel S; Weiner A; Eggener SE; Szmulewitz RZ
    Urol Oncol; 2015 Feb; 33(2):70.e1-7. PubMed ID: 25044254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trend of worsening prognosis of prostate small cell carcinoma: A population-based study.
    Wang J; Liu X; Wang Y; Ren G
    Cancer Med; 2019 Nov; 8(15):6799-6806. PubMed ID: 31518071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
    Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of radiotherapy with or without androgen-deprivation therapy for patients with intermediate-risk prostate cancer using the National Cancer Data Base.
    Amini A; Rusthoven CG; Jones BL; Armstrong H; Raben D; Kavanagh BD
    Urol Oncol; 2016 Apr; 34(4):165.e1-9. PubMed ID: 26699831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
    Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer.
    Lin CC; Gray PJ; Jemal A; Efstathiou JA
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25957435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.